DLA Piper advised ADMA Biologics, Inc. (Nasdaq: ADMA) in its underwritten follow-on public offering of common stock valued at approximately US$40 million.

ADMA is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases.

The DLA Piper team representing ADMA was led by partner David Schwartz (Short Hills), and also included associates Michael Goldstein, Brian Tribuna and Michael DeJianne (all of Short Hills).